Cargando…

CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity

Understanding the intricate dynamics between adoptively transferred immune cells and the brain tumor immune microenvironment (TIME) is crucial for the development of effective T cell–based immunotherapies. In this study, we investigated the influence of the TIME and chimeric antigen receptor (CAR) d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haydar, Dalia, Ibañez-Vega, Jorge, Crawford, Jeremy Chase, Chou, Ching-Heng, Guy, Clifford S., Meehl, Michaela, Yi, Zhongzhen, Perry, Scott, Laxton, Jonathan, Cunningham, Trevor, Langfitt, Deanna, Vogel, Peter, DeRenzo, Christopher, Gottschalk, Stephen, Roussel, Martine F., Thomas, Paul G., Krenciute, Giedre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689147/ https://www.ncbi.nlm.nih.gov/pubmed/37971169 http://dx.doi.org/10.1158/2767-9764.CRC-23-0424

Ejemplares similares

CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity
por: Haydar, Dalia, et al.
Publicado: (2023)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
por: Haydar, Dalia, et al.
Publicado: (2022)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
por: Haydar, Dalia, et al.
Publicado: (2021)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS
por: Ibanez, Jorge, et al.
Publicado: (2023)

Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?
por: Prinzing, Brooke, et al.
Publicado: (2021)

MDB-20. IMPROVING THE PERSISTENCE OF CAR T CELLS AGAINST GROUP 3 MEDULLOBLASTOMAS VIA EPIGENETIC REGULATION OF EXHAUSTION
por: Dukes, Meghan, et al.
Publicado: (2023)

GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells
por: Ibanez, Jorge, et al.
Publicado: (2023)

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019)

Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
por: Dukes, Meghan W., et al.
Publicado: (2023)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

MyD88/CD40 signaling retains CAR T cells in a less differentiated state
por: Prinzing, Brooke, et al.
Publicado: (2020)

EPEN-04. DEVELOPMENT OF B7-H3-TARGETED CAR T CELL THERAPY FOR EPENDYMOMA
por: Mehta, Sanya, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
por: Land, Craig A., et al.
Publicado: (2020)

Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma
por: Krenciute, Giedre, et al.
Publicado: (2015)

B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
por: DeRenzo, Christopher, et al.
Publicado: (2015)

Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update
por: DeRenzo, Christopher, et al.
Publicado: (2016)

Engineering naturally occurring CD7(−) T cells for the immunotherapy of hematological malignancies
por: Freiwan, Abdullah, et al.
Publicado: (2022)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells
por: Talbot, Lindsay Jones, et al.
Publicado: (2021)

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
por: Hegde, Meenakshi, et al.
Publicado: (2020)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages
por: Wilson, Taylor L., et al.
Publicado: (2022)

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
por: Zebley, Caitlin C., et al.
Publicado: (2021)

Genetically Modified T Cells to Target Glioblastoma
por: Krebs, Simone, et al.
Publicado: (2013)

Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation
por: Zebley, Caitlin C., et al.
Publicado: (2021)

CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
por: Hebbar, Nikhil, et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Informed consent in medical research
por: DeRenzo, E G
Publicado: (2001)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

The tumor vasculature an attractive CAR T cell target in solid tumors
por: Akbari, Parvin, et al.
Publicado: (2019)

CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy
por: Odé, Zelda, et al.
Publicado: (2020)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Roadblocks to success for RNA CARs in solid tumors
por: Singh, Nathan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fkqcidohsrm18eoct3t13e1q0a